This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           August 05, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store



CHEMOTHERAPY
 

Effective ovarian cancer treatment is underused, study finds
The New York Times
In 2006, the National Cancer Institute took the rare step of issuing a “clinical announcement,” a special alert it holds in reserve for advances so important that they should change medical practice. In this case, the subject was ovarian cancer. A major study had just proved that pumping chemotherapy directly into the abdomen, along with the usual intravenous method, could add 16 months or more to women’s lives. Cancer experts agreed that medical practice should change — immediately. Nearly a decade later, doctors report that fewer than half of ovarian cancer patients at American hospitals are receiving the abdominal treatment.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


SGO comments on NYT article on IP chemotherapy
In response to the New York Times article on IP chemotherapy, SGO states that IP chemotherapy is an effective means to extend lives of women with advanced ovarian cancer but is not necessarily the best option for all patients. Different regimens may be more appropriate for certain patients with advanced ovarian cancer. SGO encourages women to consult with a gynecologic oncologist, who can counsel them about all of their options, and together they can decide the course of action to take. In addition, SGO’s Outcomes Registry, which recently surpassed 2,000 patient records, is collecting information about IP chemotherapy and outcomes to help SGO members and their patients make informed choices.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Advertisement
SPONSORED CONTENT


GENETICS


Risk calculator an accurate, cost-effective prescreening tool for PTEN mutations
Healio
The PTEN Cleveland Clinic score appeared to be a cost-effective prescreening tool to identify patients with Cowden-like disease who are appropriate candidates for PTEN germline mutation testing, according to study published in the Journal of Clinical Oncology. Twenty-five percent of patients with Cowden syndrome harbor pathogenic germline PTEN mutations, which increase the risk for breast, thyroid, uterine, renal and other cancers, according to study background. However, physicians can be challenged to identify patients with Cowden-like disease who are appropriate for PTEN testing.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HPV VACCINE


Physicians blamed for low HPV vaccination rates
Medscape (free login required)
Physicians must take responsibility for improving the rate of human papillomavirus (HPV) vaccinations among teenagers, according to Anne Schuchat, MD, assistant surgeon general and director of the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention. Overall, U.S. teenagers had more vaccinations in 2014 than in previous years, including against HPV, said Dr. Schuchat, when discussing the results of a new survey published in Morbidity and Mortality Weekly Report. But most parts of the country are still lagging, primarily because physicians are not doing enough, she said.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


OBESITY


FDA okays obesity balloon device
MedPage Today
The FDA has approved a gastric balloon to treat obesity, adding to a fat-busting device arsenal that includes gastric banding and a vagal nerve stimulator. The ReShape dual balloon system is indicated for obese adults who have a body mass index (BMI) of 30 to 40, and at least one other obesity-related comorbidity such as hypertension, high cholesterol, or diabetes.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HEALTH POLICY


Worse gynecologic cancer outcomes in women enrolled in both Medicare, Medicaid
Gynecologic Cancer Advisor
Women with gynecologic cancer age 65 or older who are dually enrolled in Medicare and Medicaid have a 34 percent increased risk of all-cause mortality after diagnosis compared to women in the Medicare population who are not dually enrolled, according to a recent study published online ahead of print in Cancer. In a local population-based cohort study, Kemi Doll, MD, and fellow researchers from the University of North Carolina at Chapel Hill examined 4,522 women 65 or older — 3,702 enrolled in Medicare and 820 dually-enrolled — who were diagnosed with some form of gynecologic cancer from 2003 to 2009.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  Ovarian cancer updates from ASCO 2015:

Four prominent experts in ovarian cancer met in Chicago to provide perspectives related to progress made toward personalized therapy. More
 


BREAST CANCER


Biomarker discovery offers 'glimmer of hope' for women with aggressive breast cancer
Medical News Today
Triple-negative breast cancer is one of the most aggressive types of breast cancer. It has few treatment options, making the prognosis poor for affected women. But these women may now have a "glimmer of hope," after researchers reveal they have identified a potential drug target for the disease, according to a study published in Breast Cancer Research.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

July 29, 2015
July 22, 2015
July 15, 2015
July 8, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063